Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui

BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui

  • April 30, 2026

BeOne Medicines is paying $20 million upfront to reserve the right to buy a preclinical PD-1xCTLA-4xVEGF trispecific antibody from China’s Huahui Health.

Leave A Comment

Fields (*) Mark are Required